Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 11/20 | 0.38 |
| ▸ | CTSK | P43235 | 11/20 | 0.38 |
| ▸ | CTSB | P07858 | 13/20 | 0.37 |
| ▸ | CTSS | P25774 | 11/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 2/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295603 | 0.90 | TACR2 (0.40) | TACR2CTSLCTSKCTSBCTSS | |
| SCHEMBL6294793 | 0.90 | CTSB (0.45) | CTSLCTSKCTSBCTSSHPGDS | |
| SCHEMBL6295787 | 0.89 | CTSL (0.46) | CTSLCTSKCTSBCTSSHPGDS | |
| SCHEMBL6702836 | 0.88 | CTSL (0.41) | TACR2CTSLCTSKCTSBCTSS | |
| SCHEMBL6698937 | 0.87 | TACR2 (0.40) | TACR2CTSLCTSKCTSBCTSS | |
| SCHEMBL6300636 | 0.87 | CTSL (0.41) | TACR2CTSLCTSKCTSBCTSS | |
| SCHEMBL6295728 | 0.87 | CTSL (0.36) | TACR2CTSLCTSKCTSBCTSS | |
| SCHEMBL6295797 | 0.86 | KLKB1 (0.43) | CTSLCTSKCTSBCTSS | |
| SCHEMBL6702085 | 0.86 | HPGDS (0.45) | CTSLCTSKCTSBCTSSHPGDS | |
| SCHEMBL6699225 | 0.84 | CTSK (0.53) | CTSLCTSKCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958358-B2 | administering a cystatin; 4-tert-Butyl-N-[2-(4-hydroxyphenyl)-1S-(3-oxo-hexahydrocyclopenta[b]furan-3a-ylcarbamoyl)-ethyl]benzamide; bioassay for validation of efficacy ; Chagas' disease; parasiticide, trypanocide | AMURA THERAPEUTICS LIMITED (GB) | 2005-10-25 | — | — | US | disclosed |
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | TACR2 4235/4885CTSL 15/4885CTSK 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.